1) overactive bladder syndrome (OAB)
膀胱过度活动综合征
1.
Darifenacin is a selective muscarinic M3-receptor antagonist that has been used in patients with overactive bladder syndrome (OAB).
达非那新是一种选择性M3受体阻滞剂,临床主要用于治疗膀胱过度活动综合征。
2) Overactive bladder
膀胱过度活动症
1.
Trospium chloride:a new drug for treating overactive bladder with urge incontinence;
曲司氯铵——治疗伴有急迫性尿失禁症状的膀胱过度活动症的新药
2.
Urodynamic studies of overactive bladder with or without stress urinary incontinence in women;
膀胱过度活动症合并压力性尿失禁患者尿动力学分析
3.
Double-blind double-dummy randomized controlled multicenter clinical trial of tolterodine extended release tablet in the treatment of overactive bladder;
酒石酸托特罗定缓释片治疗膀胱过度活动症的多中心双盲双模拟随机对照临床研究
3) Overactive bladder
膀胱过度活动
1.
Urodynamic studies of interstitial cystitis and overactive bladder in women
女性间质性膀胱炎和膀胱过度活动症的尿动力学比较研究
2.
Objective : To investigate the distribution of benign prostatic hyperplasia (BPH) and overactive bladder(OAB) and the risk factors for BPH in hypertensive populations in rural community.
目的:探讨安徽农村地区中老年男性高血压人群中,良性前列腺增生(benign prostatic hyperplasia:BPH),膀胱过度活动(overactive bladder:OAB)的分布情况及其患病的危险因素,并分析比较氨氯地平,特拉唑嗪及氨氯地平联合特拉唑嗪治疗中老年男性良性前列腺增生患者膀胱过度活动的疗效。
3.
Objectives: To analyze the efficacy of biofeedback-assisted pelvic floor muscle training(BAPFMT),electrical stimulation-assisted pelvic floor muscle training (ESAPFMT), pelvic floor muscle training (PFMT) and drug therapy for overactive bladder (OAB) in female.
目的:分析生物反馈与电刺激治疗女性膀胱过度活动(overactivebladder,OAB)的近期疗效。
4) female overactive bladder
女性膀胱过度活动症
1.
Naftopidil combined with Tolterodine Tartrate in the treatment of female overactive bladder;
萘哌地尔联合舍尼亭治疗女性膀胱过度活动症的疗效观察
5) idiopath ic overactive bladder
特发性膀胱过度活动症
6) OAB-symptom
膀胱过度活动症状
1.
Objective:To study the expression and meaning of P2X1,P2X3 receptors in rat bladders with OAB-symptom which were introduced by different causes,and to investigate the possible relationship of P2X1,P2X3 receptors with OAB-symptomMethods:To make rat\'s models which have OAB-symptom produced frome different causes as experimental group,normal rats as control group.
结论:不同病因致OAB症状大鼠的膀胱病理改变不同;OAB症状膀胱上P2X1,P2X3受体表达量均显著高于正常大鼠,其中P2X1主要表达于逼尿肌,P2X3受体主要表达于膀胱上皮,P2X1,P2X3受体表达量的改变可能和OAB症状关系密切,可能为不同病因致OAB症状的共同分子生物学机制之一;对P2X1,P2X3受体在OAB症状中的分子生物学机制的深入研究,可能为将来开发新型缓解临床膀胱过度活动症状药物提理论基础。
补充资料：巨大输尿管-膀胱综合征
巨大输尿管-膀胱综合征
病名。即膀胱输 尿管反流综合征。详见该条。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条